Much of the evidence presented in the following sections on preoperative chemotherapy is discussed in an American Society of Clinical Oncology guideline that describes the selection of options for the management of these patients.[1] A 2005 meta-analysis of multiple randomized clinical trials demonstrated that preoperative chemotherapy is associated with identical disease-free survival (DFS) and overall survival (OS) as the same therapy in the adjuvant setting.[2][Level of evidence A1] In 2019, the Early Breast Cancer Trialistsâ€™ Collaborative Group performed a meta-analysis using individual patient data from 4,756 women who participated in 10 trials that compared neoadjuvant chemotherapy with the same regimen given in the adjuvant setting.[3] Compared with adjuvant therapy, neoadjuvant therapy was associated with an increased frequency of breast conservation (65% vs.